Table 3:
Cannabinoids in treatment studies
| Author, year |
Participants | Diagnosis | N | Design | Intervention | Comparator | Outcome Measurement | Relevant Findings |
|---|---|---|---|---|---|---|---|---|
| Zuardi et al. 2008 | Brazil Adult inpatients | BD-1 manic episode with psychotic features | 2 | Case report, 4 weeks | CBD 600–1200 mg PO daily, divided | Placebo, CBD + olanzapine | Mania symptoms (YMRS, BPRS) | No improvement identified with CBD monotherapy. CBD was safe and well tolerated. |
| Bergamaschi et al. 2011 | Undergrad. Students, treatment naive | SAD | 24 | Randomized double blind trail | CBD 600 mg PO x 1 dose | Placebo | Visual analogue mood scale; Public speaking Scale; Bodily symptoms scale;; skin conductance, blood pressure | Pretreatment of SAD patients with CBD significantly reduced anxiety, cognitive impairment, and discomfort in their speech performance; their measures were similar to healthy controls completing the same task |
| Jetley et al. 2015 | Canada male military personnel | PTSD | 10 | Randomized double blind cross over trial, 7 weeks each | Nabilone 0.5–3 mg PO nightly + treatment as usual | Placebo + treatment as usual | Nightmare severity (CAPS, PTSD dream rating scale), general well being (WBQ), CGI | Nabilone was significantly associated with improvement in PTSD nightmare severity (CAPS nightmare subscales, p=0.03), CGI-C (p=0.05), WBQ (p= −0.04) |
| Cameron et al. 2014 | Ontario male corrections inpatients | PTSD | 104 | Case series, open label, adjusted doses, retrospective chart review | Nabilone 0.5–6 mg PO nightly for any indication | N/A, within subject | Sleep hr/night, nights with nightmares/wk | Nabilone treatment associated with ↑ average sleep hr/night; (t= 13.7, p<0.001); ↓ nightmares/wk (t=17.9, p<0.001) 29.8% adverse events; 9.6% terminated trial |
| Roitman et al. 2014 | Israel outpatients, prior CU excluded | PTSD | 10 | Case series, open label, aadjusted doses, 3 weeks | THC 2.5 5 mg SL BID + treatment as usual | N/A, within subject | Symptom severity (CAPS, CGI), sleep quality, nightmare frequency | ↓ hyperarousal symptoms (p<0.02) jCGI-S (p<0.02) ↑ sleep quality (p<0.05) ↓ nightmare frequency (p<0.04) |
| Fraser 2009 | Ontario outpatients | PTSD with treatment resistant nightmares | 47 | Case series, open label, aadjusted doses | Nabilone 0.5 – 4 mg nightly + treatment as usual | N/A, within subject | Subjective rating nightmare intensity and hours of sleep in personal log | 72% experienced total cessation of nightmares, 13% satisfactory reduction in nightmares 28% mild-moderate side effects leading to discontinuation |